Predicting oral drug absorption in humans

Transport Processes in Pharmaceutical Systems

Volumn , Issue , 1999, Pages 377-409

  Yu, Lawrence X ^a,b   Gatlin, Larry ^c   Amidon, Gordon L ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BIOGEN   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84962461921     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203909478     Document Type: Chapter

References (86)

1. M Mayersohn. Principles of drug absorption. In: GS Banker, CT Rhodes, eds. Modern Pharmaceutics. 2nd ed. New York: Marcel Dekker, 1990, pp 23-90.
2. LX Yu, JR Crison, E Lipka, GL Amidon. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Delivery Rev 19:359-376, 1996.
3. LX Yu, LA Gatlin. Dosage form development aid: Oral drug absorption. Glaxo Wellcome Dosage Form Development Guidelines, 1997.
4. MH Jacobs. Some aspects of cell permeability to weak electrolytes. Cold Spring Harbor Symp Quant Biol 8:30-39, 1940.
5. PA Shore, BB Brodie, CAM Hogben. A mathematical model of drug absorption. J Pharmacol Exp Ther 119:361-369, 1957.
6. LS Schanker, PA Shore, BB Brodie, CAM Hogben. Absorption of drugs from the stomach. I. The rat. J Pharmacol Exp Ther 120:528-539, 1957.
7. CAM Hogben, LS Schanker, DJ Tocco, BB Brodie. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 120:540-545, 1957.
8. LS Schanker, DJ Tocco, BB Brodie, CAM Hogben. Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther 123:81-88, 1958.
9. CAM Hogben, DJ Tocco, BB Brodie, LS Schanker. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 125:275-282, 1959.
10. LS Schanker. On the mechanism of absorption from the gastrointestinal tract. J Med Pharm Chem 2:343, 1960.
11. M Rowland, TN Tozer. Clinical Pharmacokinetics. 3rd ed. Media, PA: Williams & Wilkins, 1995, pp 114-116.
12. M Gibaldi. Biopharmaceutics and Clinical Pharmacokinetics. 4th ed. Philadelphia: Lea & Lea Febiger, 1991.
13. S Suzuki, WI Higuchi, NFH Ho. Theoretical model studies of drug absorption and transport in the gastrointestinal tract. I. J Pharm Sci 59:644-651, 1970.
14. A Suzuki, WI Higuchi, NFH Ho. Theoretical model studies of drug absorption and transport in the gastrointestinal tract. II. J Pharm Sci 59:651-659, 1970.
15. D Winne. Shift of pH-absorption curves. J Pharmacok Biopharm 5:53-94, 1977.
16. B Testa, P-A Carrupt, P Gaillard, F Billois, P Weber. Lipophilicity in molecular modeling. Pharm Res 13:335-343, 1996.
17. H van de Waterbeemd, B Testa. The parameterization of lipophilicity and other structural properties in drug design. In: B. Testa, ed. Advances in Drug Research, Vol. 16. London: Academic Press, 1987, pp 87-227.
18. BH Stewart, OH Chan, N Jezyk, D Fleisher. Discrimination between drug candidate using models for evaluation of intestinal absorption. Adv Drug Deliv Rev 23:27-45, 1997.
19. RN Smith, C Hansch, MM Ames. Selection of a reference partitioning system for drug design work. J Pharm Sci 64:599-606, 1975.
20. V Austel, E Kutter. Absorption, distribution and metabolism of drugs. In: JG Topless, ed. Quantitative Structure-Activity Relationships of Drugs. New York: Academic Press, 1980, pp 437-496.
21. A Leo, C Hansch, D Elkins. Partition coefficients and their uses. Chem Rev 71: 525-616, 1977.
22. SH Yalkowsky, W Morozowich. A physical chemical basis of the design of orally active prodrugs. Drug Des 9:122-185, 1980.
23. I Komiya, JY Park, A Kamani, NFH Ho, WI Higuchi. Physical model studies on the simultaneous fluid flow and absorption of steroids in the rat intestines. Int J Pharm 4:249-262, 1980.
24. NFH Ho, JY Park, W Morozowich, WI Higuchi. Physical model approach to the design of drugs with improved intestinal absorption. In: EB Roche, ed. Design of Biopharmaceutical Properties Through Prodrugs and Analogs. Washington DC: American Pharmaceutical Association, Acad Pharm Sci, 1977, pp 136-227.
25. JBM Van Bree, AG De Boer, M Danhof, L Gisel, DD Breimer. Characterization of an in vitro blood-brain barrier: Effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 247: 1233-1239, 1988.
26. A Buur, L Trier, C Magnusson, P Artursson. Permeability of 5-fluorouracil and prodrugs in Caco-2 cell monolayers. Int J Pharm 129:223-231, 1996.
27. PS Burton, RA Conradi, NFH Ho, AR Hilgers, RT Borchard. How structure features influence the biomembrane permeability of peptides. J Pharm Sci 85:1336-1340, 1996.
28. JB Dressman, GL Amidon, D Fleisher. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74:588-589, 1985.
29. P Macheras, MY Symillides. Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept. Biopharm Drug Dispos 10:43-53, 1989.
30. GL Amidon, PJ Sinko, D Fleisher. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carriermediated compounds. Pharm Res 5:651-654, 1988.
31. PJ Sinko, GD Leesman, GL Amidon. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res 8:979-988, 1991.
32. PJ Sinko, GD Leesman, GL Amidon. Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: Theoretical development and applications. Pharm Res 10:271-275, 1993.
33. GL Amidon, H Lennernas, VP Shah, JR Crison. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420, 1995.
34. DM Oh, PJ Sinko, GL Amidon. Predicting oral drug absorption in humans: A macroscopic mass balance approach for passive and carrier-mediated compounds. In:DZ D’Argenio, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. New York: Plenum Press, 1990, pp 3-11.
35. PJ Sinko, GL Amidon. Characterization of the oral absorption of ß-lactam antibiotics. I. Cephalosporins: Determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res 5:645-650, 1988.
36. PJ Sinko, GL Amidon. Characterization of the oral absorption of ß-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci 78:723-727, 1989.
37. DM Oh, PJ Sinko, GL Amidon. Characterization of the oral absorption of ß-lactam: Effect of the α-amino side chain group. J Pharm Sci 82:897-900, 1993.
38. P Artursson, K Palm, K Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 22:67-84, 1996.
39. P Artursson, J Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885, 1991.
40. BH Stewart, OH Chan, RH Lu, EL Reyner, HL Schmid, HW Hamilton, BA Steinbaugh, MD Taylor. Comparison of intestinal permeabilities determined in multiple in vitro and in situ model: Relationship to absorption in humans. Pharm Res 12:693-699, 1995.
41. JN Cogburn, MG Donovan, CS Schasteen. A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm Res 9:210-216, 1991.
42. W Rubas, N Jezyk, GM Grass. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 10:113-118, 1993.
43. DM Oh, RL Curl, GL Amidon. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: A mathematical model. Pharm Res 10:264-270, 1993.
44. JR Crison. Estimating the dissolution and absorption of water insoluble drugs in the small intestine. PhD dissertation, The University of Michigan, Ann Arbor, MI, 1993.
45. AJ Jounela, PJ Pentikainen, A Sothman. Effect of particle size on the bioavailability of digoxin. Eur J Clin Pharmacol 8:365-370, 1975.
46. M Kraml, J Dubuc, R Gaudry. Gastrointestinal absorption of griseofulvin: II. Influence of particle size in man. Antibiot Chemother 12:239-242, 1962.
47. JR Crison, GL Amidon. Expected variation in bioavailability for water insoluble drugs. In: HH Blume, KK Midha, eds. Bio-International 2, Bioavailability, Bioequi valence and Pharmacokinetic Studies. Stuttgart:Medpharm Scientific Publishers, 1995, pp 301-309.
48. JR Crison, GL Amidon. The effect of particle size distribution on drug dissolution: A mathematical model for predicting dissolution and absorption of suspensions in the small intestine. Pharm Res 10:S170, 1992.
49. PF Ni, NFH Ho, JF Fox, H Leuenberger, WI Higuchi. Theoretical model studies of intestinal drug absorption. V. Nonsteady-state fluid flow and absorption. Int J Pharm 5:33-47, 1980.
50. NFH Ho, JY Park, PF Ni, WI Higuchi. Advanced quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. In: W Crouthanel, AC Sarapu, eds. Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches. Washington DC: American Pharmaceutical Association, 1983, pp 27-106.
51. R Zipp, NFH Ho. Nonsteady state model of absorption of suspensions in the GI tract: Coupling multi-phase intestinal flow with blood level kinetics. Pharm Res 10: S210, 1993.
52. RJ Leipold. Description and simulation of a tubular, plug-flow model to predict the effect of bile sequestrants on human bile salt excretion. J Pharm Sci 84:670-672, 1995.
53. GE Amidon, NFH Ho, AB Frech, WI Higuchi. Predicted absorption rates with simultaneous bulk fluid flow in the intestinal tract. J Theor Biol 89:195-210, 1981.
54. NFH Ho, HP Merkle, WI Higuchi. Quantitative, mechanistic and physiologically realistic approach to the biopharmaceutical design of oral drug delivery systems. Drug Deliv Ind Pharm 9:1111-1184, 1983.
55. BC Goodacre, RJ Murry. Quantitative, mechanistic and physiologically realistic approach to the biopharmaceutical design of oral drug delivery systems. J Clin Hosp Pharm 6:117-133, 1981.
56. JB Dressman, D Fleisher, GL Amidon. Physicochemical model for dose-dependent drug absorption. J Pharm Sci 73:1274-1279, 1984.
57. JB Dressman, D Fleisher. Mixing-tank model for predicting dissolution rate control of oral absorption. J Pharm Sci 75:109-116, 1986.
58. RJ Hintz, KC Johnson. The effect of particle size distribution on the dissolution rate and oral absorption. Int J Pharm 51:9-17, 1989.
59. ATK Lu, ME Frisella, KC Johnson. Dissolution modeling: Factors affecting the dissolution rates of polydisperse powders. Pharm Res 10:1308-1314, 1993.
60. KC Johnson, AC Swindell. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 13:1795-1798, 1996.
61. RL Oberle, GL Amidon. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: An explanation for the double peak phenomenon. J Pharmacok Biopharm 15:529-544, 1987.
62. GD Leesman, PJ Sinko, GL Amidon. Simulation of oral drug absorption: Gastric emptying and gastrointestinal motility. In: PG Welling, FLS Tse, eds. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1989, pp 267-284.
63. P Luner, GL Amidon. Description and simulation of a multiple mixing tank model to predict the effect of bile sequestrants on bile salt excretion. J Pharm Sci 82:311-318, 1993.
64. LX Yu, JR Crison, GL Amidon. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 140:111-118, 1996.
65. LX Yu, GL Amidon. Characterization of small intestinal transit time distribution in humans. Int J Pharm 171:157-163, 1998.
66. LX Yu, JR Crison, GL Amidon. A strategic approach for predicting oral drug absorption in humans. Pharm Res 12:S8, 1995.
67. LX Yu, GL Amidon. Saturable small intestinal drug absorption in humans: Modeling and explanation of the cefatrizine data. Eur J Pharm Biopharm 45:199-203, 1998.
68. SY Choe, E Lipka, LX Yu, JR Crison, GL Amidon. Optimization of dosage form release parameters based on pharmacokinetic and gastrointestinal transit time considerations. Pharm Res 13:S292, 1996.
69. E Lipka, LX Yu, D Liu, JR Crison, GL Amidon. Evaluation of the intestinal permeability of ß-blocker drugs and their potential for oral controlled release. Proc Int Symp Controlled Release Bioact Mater 22:366-367, 1995.
70. SS Davis, JG Hardy, JW Fara. Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892, 1986.
71. NW Weisbrodt. Motility of the small intestine. In: LR Johnson, ed. Physiology of the Gastrointestinal Tract. New York: Raven Press, 1989, pp 631-664.
72. P Kerlin, A Zinsmeister, S Phillips. Relationship of motility to flow of contents in the human small intestine. Gastroenterology 82:701-706, 1982.
73. SH Kubo, RJ Cody. Clinical pharmacokinetics of the angiotension converting enzyme inhibitors. Clin Pharmacokinet 10:377-391, 1985.
74. LLB Ponto, RD Schoenwald. Furosemide: A pharmacokinetics/pharmacodynamics review. Clin Pharmacok 18:381-408, 1993.
75. DS Davies. Pharmacokinetics of terbutaline after oral administration. Eur J Resp Dis Suppl 65:111-117, 1984.
76. WD Mason, N Winer, G Kochak, I Cohen, R Bell. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther 25:408-415, 1979.
77. LZ Benet, S Øie, JB Schwartz. Design and optimization of dosage regiments; pharmacokinetic data. In: JG Hardman, LE Limbird, AG Gilman, eds. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996, pp 1707-1793.
78. American Hospital Formulary Service. 1996 Edition, p 1982.
79. JW Paterson, ME Conolly, CT Dollery, A Hayes, RG Cooper. The pharmacodynamics and metabolism of propranolol in man. Pharmacol Clin 2:127-133, 1970.
80. FLS Tse, JM Jaffe, AJ Troendle. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32:630-638, 1992.
81. E Eichelbaum, HR Ochs, G Roberts, A Somogyi. Pharmacokinetics and metabolism of antipyrine after intravenous and oral administration. Arzneim-Forsch 32:575-578, 1982.
82. MPfeffer, RC Gaver, J Ximenez. Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine. Antimicrob Agents Chemother 24:915-920, 1983.
83. AM Metcalf, SF Phillips, AR Zinsmeister, RL MacCarty, RW Beart, BG Wolff. Simplified assessment of segmental colonic transit. Gastroenterology 92:40-47, 1987.
84. RC Gaver, G Deeb. Disposition of 14C-cefatrazine in man. Drug Dis Metab Dispos 8:157-162, 1980.
85. H Lennernas, O Ahrenstedt, R Hallgren, L Knutson, M Ryde, LK Paalzow. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 9:1243-1251, 1992.
86. H Lennernas. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 49:627-638, 1997.